Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BP101 nasal spray for hypoactive sexual desire disorder
ACTRN12620001356954Phase 2Terminated
- Sponsor
- OVB
- Start
- Jan 2021
- Modality
- Small Molecules, Peptides
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of BP101 in hypoactive sexual desire disorder (HSDD), sponsored by OVB. Primary endpoints: Change in Female Sexual Function Index Desire domain score and Change in Female Sexual Distress Scale-Desire/Arousal/Orgasm Item 13 score. Started Jan 2021; status: terminated.
02
Drugs
BP101
03
Conditions
hypoactive sexual desire disorder (HSDD)
Beyond the preview
Go deeper on ACTRN12620001356954.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12620001356954.